Expression of e-cadherin and β-catenin in human esophageal squamous cell carcinoma: relationships with prognosis

Table 1 Relationships between espression of E-cadherin and β-catenin an clinicopathological parameters in patients with ESCC

Group	Total	E-cadherin			P	β-catenin			P
		+	±	-	rs	+	±	-	rs
Histologic grade
I	17	8	8	1		9	6	2
II	69	25	33	11	0.001	21	28	20	0.014
III	20	3	7	10	-0.309	2	12	6	-0.238
Tumor size (cm)
< 3.0	10	6	2	2		0	5	5
3.0-5.0	41	16	18	7		15	15	11
5.0-7.0	44	11	24	9	0.054	12	24	8	0.213
≤ 7.0	11	3	4	4	-0.187	5	2	4	-0.212
Clinical staging
I	2	2	0	0		0	2	0
IIa	31	16	11	4		13	13	5
IIb	10	2	5	3	0.013	3	2	5	0.124
III	60	15	31	14	-0.241	6	27	17	-0.150
IV	3	1	111	1		0	2	1
Venous invasion
Yes	27	5	14	8	0.042	6	12	9	0.237
No	79	31	34	14	-0.198	26	34	19	-0.116
Lymph nodemetastasis
Yes	47	11	22	14	0.014	13	21	13	0.646
No	59	25	26	8	-0.239	19	25	15	-0.045

Table 2 Relationships between E-cadherin and β-catenin expression in ESCC

E-cadherin	Total	β-catenin
		+	±	-
+	36	17	13	6
±	48	11	24	13
-	22	4	9	9
Total	106	32	46	28

r_s = 0.270, P = 0.005.

Table 3 Multivariate results in Cox proportional hazards analysis for patients with ESCC

Variables	Category (Value)	β	Wald	P Value	HR	95%CI
Overall survival (n = 106)
location (mid-thoracic)	No/Yes (0/l)	0.650	5.665	0.017	1.916	1.112-3.272
Lymph node metastasis	No/Yes (0/l)	0.599	5.893	0.015	1.821	1.1222-953
Venous invasion	No/Yes (0/l)	1.147	18.633	< 0.00l	3.148	1.870-5.229
Clinical staging	I/II/III/IV (0/1/2/3)	0.420	8.475	0.004	1.521	1.147-2.018
E-cadherin	-/ ± /+ (0/1/2)	-0.431	5.687	0.017	0.650	0.456-0.926
Disease-free survival (n = 96)
Gender	M/F (0/1)	0.675	4.786	0.029	1.965	1.073-3.598
Tumor size	Continue	0.179	4.302	0.038	1.196	1.010-1.417
Clinical staging	I/II/III/IV (0/1/2/3)	0.272	3.233	0.042	1.313	0.976-1.767
Location (mid-thoracic)	No/Yes (0/l)	0.615	4.111	0.043	1.849	1.021-3.349
Venous invasion	No/Yes (0/l)	0.982	9.797	0.002	2.671	1.444--4.942
E-cadherin	-/ ± /+ (0/1/2)	-0.397	4.479	0.034	0.672	0.465-0.971